Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NAT1 | P18440 | 1/20 | 0.31 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8784604 | 0.89 | ABCG2 (0.39) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7352872 | 0.88 | ABCG2 (0.41) | AGTR1ABCG2DRD1DRD2DRD4 | |
| SCHEMBL30743612 | 0.86 | ABCG2 (0.55) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL7352477 | 0.84 | ABCG2 (0.41) | AGTR1ABCG2DRD1DRD2DRD4 | |
| SCHEMBL4638846 | 0.83 | ABCG2 (0.46) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL15391225 | 0.83 | AGTR1 (0.47) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL9033772 | 0.81 | AGTR1 (0.41) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL4638349 | 0.81 | AGTR1 (0.47) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL3875056 | 0.80 | AGTR1 (0.49) | AGTR1ABCG2POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL9429727 | 0.80 | AGTR1 (0.43) | AGTR1ABCG2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5371233-A | 2-(tetrazol-5-yl)-1,1'-biphenyl derivatives, their preparation and their use as synthetic intermediates | SYNTHELABO (FR) | 1994-12-06 | — | — | US | claimed |
| EP-1384717-B1 | 2-(2'-triphenylmethyl-2'H-tetrazol-5'-yl)phenylboronic acid intermediates for the synthesis of A II receptor antagonists | DU PONT (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20070072923-A1 | Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070072923-A1 | Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-03-29 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1384717-A2 | Tetrazolylphenylboronic acid intermediates for the synthesis of A II receptor antagonists | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-01-28 | — | — | EP | disclosed |
| EP-0643704-B1 | TETRAZOLYLPHENYLBORONIC ACID INTERMEDIATES FOR THE SYNTHESIS OF AII RECEPTOR ANTAGONISTS | DU PONT (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-1998027077-A1 | 2,1,3-BENZOTHIA(OXA)DIAZOLE DERIVATIVES AND THEIR USE AS ENDOTHELIN-RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 1998-06-25 | — | — | WO | disclosed |
| EP-0760814-A1 | A PROCESS FOR PREPARING 1-BUTYL-2-[2'-(2H-TETRAZOL-5-YL)-BIPHENYL-4-YLMETHYL]-1H-INDOLE-3-CARBOXYLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1997-03-12 | — | — | EP | disclosed |
| US-5468867-A | Process for preparing1-butyl-2-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl1-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-11-21 | — | — | US | disclosed |
| US-5446121-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5412102-A | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid | SYNTEX (U.S.A.) INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5371233-A | 2-(tetrazol-5-yl)-1,1'-biphenyl derivatives, their preparation and their use as synthetic intermediates | SYNTHELABO (FR) | 1994-12-06 | — | — | US | disclosed |
| US-5369114-A | Angiotensin II antagonist | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-11-29 | — | — | US | disclosed |
| US-5310928-A | Process for preparing biphenyltetrazole compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0550313-A1 | 2-(Tetranol-5-yl)-(1,1'-biphenyl)derivatives, their preparation and use as intermediates | SYNTHELABO (FR) | 1993-07-07 | — | — | EP | disclosed |
| US-5206374-A | Process for preparing tetrazolylphenylboronic acid intermediates | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-04-27 | — | — | US | disclosed |
| US-5130439-A | Tetrazolylphenylboronic acid intermediates for the synthesis of AII receptor antagonists | E.I. DU PONT DE NEMOURS AND COMPANY, A CORPORATION OF DELAWARE | 1992-07-14 | — | — | US | disclosed |
| EP-0456442-A1 | Quinoline derivatives, process for their preparation and their use as medicaments | ZENECA LIMITED (GB) | 1991-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072923-A1 | Process for producing 2'-(1h-tetrazol-5-yl)biphenyl-4-carbaldehyde | TH, CYP4B1, ABL1 | AGTR1 816/4885ABCG2 118/4885DRD1 931/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | AGTR1 2/4885ABCG2 1983/4885DRD1 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.